Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Net Cash Flow (2018 - 2025)

Historic Net Cash Flow for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Q3 2025 value amounting to -$16.1 million.

  • Arcturus Therapeutics Holdings' Net Cash Flow rose 3042.63% to -$16.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$56.8 million, marking a year-over-year increase of 2423.05%. This contributed to the annual value of -$55.0 million for FY2024, which is 2193.54% down from last year.
  • According to the latest figures from Q3 2025, Arcturus Therapeutics Holdings' Net Cash Flow is -$16.1 million, which was up 3042.63% from -$20.5 million recorded in Q2 2025.
  • In the past 5 years, Arcturus Therapeutics Holdings' Net Cash Flow ranged from a high of $154.2 million in Q4 2022 and a low of -$63.9 million during Q1 2023
  • Moreover, its 5-year median value for Net Cash Flow was -$20.2 million (2023), whereas its average is -$11.9 million.
  • Data for Arcturus Therapeutics Holdings' Net Cash Flow shows a peak YoY increase of 45546.85% (in 2022) and a maximum YoY decrease of 138838.74% (in 2022) over the last 5 years.
  • Quarter analysis of 5 years shows Arcturus Therapeutics Holdings' Net Cash Flow stood at -$43.4 million in 2021, then surged by 455.47% to $154.2 million in 2022, then tumbled by 113.07% to -$20.2 million in 2023, then skyrocketed by 99.26% to -$150000.0 in 2024, then tumbled by 10638.0% to -$16.1 million in 2025.
  • Its Net Cash Flow stands at -$16.1 million for Q3 2025, versus -$20.5 million for Q2 2025 and -$20.1 million for Q1 2025.